Active/Enrolling Clinical Trials
Search by condition, physician, number or keyword
There are currently 301 clinical trials active/enrolling at UHealth, the University of Miami Health System.
Search Results
There are 151 clinical trials matching "Cancer"
GOG 0263 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.
Investigator: Joseph Lucci
Institutional Protocol #: 20120529
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Gynecologic Cancer
Phase: Phase III
Enrolling Since: 6/12/2013
A Randomized Controlled Study of Yondelis (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Protocol #ET743-SAR-3007
Investigator: Gustavo Fernandez
Institutional Protocol #: 20120545
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Bone and Soft Tissue Cancers
Phase: Phase III
Enrolling Since: 6/4/2013
Phase II Trial Using Cetuximab (Erbitux) and Taxotere with Low Dose Fractioned Radiation for Recurrent Unresectable Locally Advance Head and Neck Carcinoma (2009019)
Investigator: Matthew Abramowitz
Institutional Protocol #: 20090467
National Clinical Trials Identifier: NCT01794845
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: Phase II
Enrolling Since: 5/30/2013
Rtog 1008: a Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salvary Gland Tumors
Investigator: Michael Samuels
Institutional Protocol #: 20130022
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: Phase II
Enrolling Since: 5/14/2013
RTOG 1203: A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
Investigator: Lorraine Portelance
Institutional Protocol #: 20120862
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Gynecologic Cancer
Phase: Phase III
Enrolling Since: 5/14/2013
Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 versus Investigator?s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20120479
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase III
Enrolling Since: 5/14/2013
Phase II Study of SPI-1620 in Combination with Docetaxel as a Second-Line Treatment for Patients with Advanced Biliary Cancer
Investigator: Caio Max Rocha Lima
Institutional Protocol #: 20121030
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pancreatic, Liver, and Related Cancers
Phase: Phase II
Enrolling Since: 5/10/2013
Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3 Expressing Hematologic Malignancies
Investigator: Ronan Swords
Institutional Protocol #: 20120908
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase I
Enrolling Since: 5/9/2013
GOG-0274: ?A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG 0902/RTOG 1174)
Investigator: Joseph Lucci
Institutional Protocol #: 20120228
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Gynecologic Cancer
Phase: Phase III
Enrolling Since: 5/8/2013
Randomized Double-Blind Phase II Trial of Everolimus versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Investigator: Zoukaa Sargi
Institutional Protocol #: 20100739
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: Phase II
Enrolling Since: 5/3/2013
A Phase III Study of FOLFIRINOX With or Without HyperAcute Pancreas (algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Investigator: Peter Hosein
Institutional Protocol #: 20120981
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pancreatic, Liver, and Related Cancers
Phase: Phase III
Enrolling Since: 5/2/2013
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute- Pancreatic Cancer Vaccine in Subject with Surgically Resected Pancreatic Cancer
Investigator: Caio Max Rocha Lima
Institutional Protocol #: 20120297
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pancreatic, Liver, and Related Cancers
Phase: Phase III
Enrolling Since: 4/22/2013
A Phase IB, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are 60 Years or Older
Investigator: Ronan Swords
Institutional Protocol #: 20120902
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase I
Enrolling Since: 4/5/2013
C25003: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Investigator: Joseph Rosenblatt
Institutional Protocol #: 20120841
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase III
Enrolling Since: 3/28/2013
RTOG 1115: Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
Investigator: Adrian Ishkanian
Institutional Protocol #: 20120978
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase III
Enrolling Since: 3/21/2013
The Beacon Study (Breast Cancer Outcomes With Nktr-102): a Phase 3 Open-Label, Randomized, Multicenter Study of Nktr-102 Versus Treatment of Physician's Choice (tpc) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Investigator: Stefan Gluck
Institutional Protocol #: 20120302
National Clinical Trials Identifier: NCT01492101
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase III
Enrolling Since: 3/20/2013
A two-cohort, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab and vinorelbine in first line patients with HER2-positive advanced (metastatic or locally advanced) breast cancer.
Investigator: Eugene Ahn
Institutional Protocol #: 20120350
National Clinical Trials Identifier: NCT01565083
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase II
Enrolling Since: 3/11/2013
A Randomized Study of Radiation Hypofractionation via Extended versus Accelerated Therapy (HEAT) For Prostate Cancer
Investigator: Matthew Abramowitz
Institutional Protocol #: 20110491
National Clinical Trials Identifier: NCT01794403
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase III
Enrolling Since: 2/27/2013
A Phase II randomized, double-blind, placebo controlled study to assess safety, tolerability and effect on tumor size of MCS110 in patients with pigmented villonodular synovitis (PVNS)
Investigator: Jonathan Trent
Institutional Protocol #: 20120056
National Clinical Trials Identifier: NCT01643850
Division: Cancer Center
Therapeutic Area: Bone and Soft Tissue Cancers
Phase: Phase I/II
Enrolling Since: 2/21/2013
ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Investigator: Julio Barredo
Institutional Protocol #: 20110453
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 2/19/2013
Safety and Efficacy of Single Agent Adjuvant Trastuzumab (Herceptin) in Older Women with Early Stage and Locally Advanced Breast Cancer: A Phase II Trial
Investigator: Eugene Ahn
Institutional Protocol #: 20110724
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase II
Enrolling Since: 2/18/2013
AMC #070: A phase I/II study of lenalidomide in patients with AIDS-associated Kaposi?s sarcoma, version 8.0 dated 09/22/2011
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20100997
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Bone and Soft Tissue Cancers
Phase: Phase I/II
Enrolling Since: 2/14/2013
G025632: a Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Bevacizumab, and Associated Biomarkers, in Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-Line Treatment of Patients With HER2 Negative Metastatic Breast Cancer
Investigator: Charles Vogel
Institutional Protocol #: 20120534
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase III
Enrolling Since: 2/13/2013
DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
Investigator: Michele Morris
Institutional Protocol #: 20120667
National Clinical Trials Identifier: NCT01691248
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase III
Enrolling Since: 1/18/2013
ARST0921 - A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
Investigator: Julio Barredo
Institutional Protocol #: 20121038
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase II
Enrolling Since: 12/17/2012
Vascular endothelial inflammation and dysfunction in pediatric long-term cancer survivors
Investigator: Tracie Miller
Institutional Protocol #: 20070584
National Clinical Trials Identifier: N/A
Division: Pediatrics
Therapeutic Area: Cardiology
Phase: N/A
Enrolling Since: 12/14/2012
BKM120F2302: A Phase III Randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-Negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment
Investigator: Charles Vogel
Institutional Protocol #: 20120567
National Clinical Trials Identifier: NCT01610284
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase III
Enrolling Since: 12/11/2012
A Randomized, Phase 2 Trial of Aezs-108 in Chemotherapy Refractory Triple Negative (er/pr/HER2-Negative) Lhrh-r Positive Metastatic Breast Cancer
Investigator: Alberto Montero
Institutional Protocol #: 20111036
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase II
Enrolling Since: 12/3/2012
A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors
Investigator: John Goldberg
Institutional Protocol #: 20120420
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase I
Enrolling Since: 9/28/2012
ACNS0822 - A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma
Investigator: Julio Barredo
Institutional Protocol #: 20120325
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase II/III
Enrolling Since: 9/10/2012
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)
Investigator: Krishna Komanduri
Institutional Protocol #: 20110320
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase II
Enrolling Since: 9/5/2012
ARST08P1: A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
Investigator: Julio Barredo
Institutional Protocol #: 20110534
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Pilot/Feasibility
Enrolling Since: 8/15/2012
Phase II Trial of SOM230 (Pasireotide LAR) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Investigator: Lynn Feun
Institutional Protocol #: 20100650
National Clinical Trials Identifier: NCT01639352
Division: Cancer Center
Therapeutic Area: Pancreatic, Liver, and Related Cancers
Phase: Phase II
Enrolling Since: 7/23/2012
AAML1031 - A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.
Investigator: Julio Barredo
Institutional Protocol #: 20120324
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 7/16/2012
A Phase I Trial of Dendritic Cell Vaccination With and Without Inhibition of Myeloid Derived Suppressor Cells by Gemcitabine Pre-Treatment For Children And Adults With Sarcoma.
Investigator: John Goldberg
Institutional Protocol #: 20110462
National Clinical Trials Identifier: NCT01803152
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase I
Enrolling Since: 7/16/2012
MK Study: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant (EMEND®) and Fosaprepitant Dimeglumine (EMEND® For Injection) in Pediatric Patients Receiving Emetogenic (vomit inducing) Chemotherapy
Investigator: John Goldberg
Institutional Protocol #: 20091068
National Clinical Trials Identifier: NCT00818259
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase I
Enrolling Since: 7/11/2012
An Open-Label, Multicenter Phase 1b/2 Study of E7080 Alone, and in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment.
Investigator: Pasquale Benedetto
Institutional Protocol #: 20110366
National Clinical Trials Identifier: NCT01136733
Division: Cancer Center
Therapeutic Area: Stomach and Esophageal Cancer
Phase: N/A
Enrolling Since: 6/25/2012
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous hematopoietic Cell Transplants (HCTs)
Investigator: Krishna Komanduri
Institutional Protocol #: 20110112
National Clinical Trials Identifier: NCT01229267
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: N/A
Enrolling Since: 6/15/2012
NCBP 6637-01: A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients.
Investigator: Martin Andreansky
Institutional Protocol #: 20120231
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase II
Enrolling Since: 6/11/2012
AALL1131 - A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Investigator: Julio Barredo
Institutional Protocol #: 20110919
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 6/11/2012
P7977-2025 An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre- Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Investigator: Eugene Schiff
Institutional Protocol #: 20111164
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pancreatic, Liver, and Related Cancers
Phase: Phase II/III
Enrolling Since: 5/16/2012
An Extension Protocol for Subjects Who Were Previously Enrolled in other ARQ 197 Protocols.
Investigator: John Goldberg
Institutional Protocol #: 20100674
National Clinical Trials Identifier: NCT01178411
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase I
Enrolling Since: 4/24/2012
AMC PROTOCOL #078: A Phase 1 Study of Vorinostat in Combination with Paclitaxel and Carboplatin in Solid Tumors (with Focus on Upper Aerodigestive Cancers) in Persons with HIV Infections
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20110391
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Bone and Soft Tissue Cancers
Phase: Phase I
Enrolling Since: 3/23/2012
Phase 1b Open-Label Study of the Safety and Clinical Activity of Crizotinib (pf-02341066) in Tumors With Genetic Events Involving the Anaplastic Lymphoma Kinase (alk) Gene Locus
Investigator: Alexandra Stefanovic
Institutional Protocol #: 20110297
National Clinical Trials Identifier: NCT01121588
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase I
Enrolling Since: 3/7/2012
A Multicenter Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine
Investigator: Alexandra Stefanovic
Institutional Protocol #: 20110605
National Clinical Trials Identifier: NCT01397825
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase I/II
Enrolling Since: 3/2/2012
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Relapsed/Refractory Multiple Myeloma who Have Failed at Least two Prior Therapies
Investigator: Denise Pereira
Institutional Protocol #: 20110069
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: N/A
Enrolling Since: 3/1/2012
ADVL0921: A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias
Investigator: Julio Barredo
Institutional Protocol #: 20111126
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase II
Enrolling Since: 2/24/2012
Rtog 1005: a Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Investigator: Cristiane Takita
Institutional Protocol #: 20110709
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase III
Enrolling Since: 2/14/2012
RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected head and Neck Cancer
Investigator: Michael Samuels
Institutional Protocol #: 20100572
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: Phase III
Enrolling Since: 2/13/2012
MAVERICC: A RANDOMIZED PHASE II STUDY OF BEVACIZUMAB/mFOLFOX6 VS. BEVACIZUMAB/FOLFIRI WITH BIOMARKER STRATIFICATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER
Investigator: Caio Max Rocha Lima
Institutional Protocol #: 20110614
National Clinical Trials Identifier: NCT01374425
Division: Cancer Center
Therapeutic Area: Colorectal Cancer
Phase: Phase II
Enrolling Since: 1/31/2012
A Phase I Study of Nelfinavir added to Cisplatin chemotherapy concurrent with Pelvic Radiation for locally advanced cervical cancer (II-IVA)
Investigator: Fiona Simpkins
Institutional Protocol #: 20100153
National Clinical Trials Identifier: NCT01485731
Division: Cancer Center
Therapeutic Area: Gynecologic Cancer
Phase: Phase I
Enrolling Since: 1/9/2012
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (rs) of 25 or Less.
Investigator: Mohammad Jahanzeb
Institutional Protocol #: 20110676
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase III
Enrolling Since: 12/7/2011
RTOG 0848: A Phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma
Investigator: Lorraine Portelance
Institutional Protocol #: 20110584
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pancreatic, Liver, and Related Cancers
Phase: Phase III
Enrolling Since: 12/7/2011
RTOG 1016: Phase III trial of radiotheraphy plus Cetuximab versus Chemoradiotheraphy in HPV associates oropharynx cancer
Investigator: Nagy Elsayyad
Institutional Protocol #: 20110580
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: Phase III
Enrolling Since: 12/7/2011
Rtog 0913: Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
Investigator: Fazilat Ishkanian
Institutional Protocol #: 20110296
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Neurological Cancer
Phase: Pilot/Feasibility
Enrolling Since: 12/7/2011
ACNS0821 Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Investigator: Julio Barredo
Institutional Protocol #: 20110918
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase II
Enrolling Since: 11/18/2011
RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy (RT) With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy.
Investigator: Aaron Wolfson
Institutional Protocol #: 20100394
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Gynecologic Cancer
Phase: Phase III
Enrolling Since: 10/14/2011
RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy (RT) With or Without Short-Term Androgen Deprivation Therapy (ADT) for Patients With Intermediate-Risk Prostate Cancer
Investigator: Alan Pollack
Institutional Protocol #: 20100320
National Clinical Trials Identifier: NCT00936390
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase III
Enrolling Since: 8/29/2011
A Randomized, Double-Blinded, Placebo-Controlled, Multi-institutional, Cross-Over, Phase II.5 study of Saracatinib (AZD0503), a Selective SRC Kinase Inhibitor, in patients with Recurrent Osteosarcoma Localized to the lung.
Investigator: John Goldberg
Institutional Protocol #: 20100585
National Clinical Trials Identifier: NCT00752206
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase II
Enrolling Since: 8/1/2011
Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy with Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20100391
National Clinical Trials Identifier: NCT01000285
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase I/II
Enrolling Since: 7/26/2011
AMC PROTOCOL #053: Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Lymphoma
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20100388
National Clinical Trials Identifier: NCT00598169
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Pilot/Feasibility
Enrolling Since: 6/9/2011
Evaluation of Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors
Investigator: Radka Stoyanova
Institutional Protocol #: 20100809
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Neurological Cancer
Phase: Pilot/Feasibility
Enrolling Since: 6/8/2011
T2009-012 A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies.
Investigator: John Goldberg
Institutional Protocol #: 20110263
National Clinical Trials Identifier: NCT01321346
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase I
Enrolling Since: 6/6/2011
A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Investigator: Matthew Abramowitz
Institutional Protocol #: 20101056
National Clinical Trials Identifier: NCT01411345
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase III
Enrolling Since: 6/1/2011
ACNS0333: Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation.
Investigator: Julio Barredo
Institutional Protocol #: 20110244
National Clinical Trials Identifier: NCT00653068
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 5/26/2011
Elevated Health Risk Among Patients with Non-Hodgkin’s Lymphoma (NHL) and Their Caregivers: Pilot Study
Investigator: Youngmee Kim
Institutional Protocol #: 20100411
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: N/A
Enrolling Since: 5/18/2011
A Phase III Trial Of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial
Investigator: Alan Pollack
Institutional Protocol #: 20100635
National Clinical Trials Identifier: NCT01411332
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase III
Enrolling Since: 5/16/2011
Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination with Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for Relapsed Epstein Barr Virus Associated Lymphoma
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20090166
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase II
Enrolling Since: 4/22/2011
A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination with Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin with Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD)
Investigator: John Goldberg
Institutional Protocol #: 20110140
National Clinical Trials Identifier: NCT01324180
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase I
Enrolling Since: 3/21/2011
Psychophysiologic mechanisms related to cancer morbidities among underserved Black women after breast cancer treatment
Investigator: Suzanne Lechner
Institutional Protocol #: 20100816
National Clinical Trials Identifier: N/A
Division: Psychiatry
Therapeutic Area: Other
Phase: N/A
Enrolling Since: 3/16/2011
Molecular Genetics of Radiation-Induced Skin Toxicities in a Tri-Racial/Ethnic post-Mastectomy Breast Cancer Cohort
Investigator: Jean Wright
Institutional Protocol #: 20100655
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: N/A
Enrolling Since: 3/8/2011
ACNS0334, A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate
Investigator: Julio Barredo
Institutional Protocol #: 20080544
National Clinical Trials Identifier: NCT00336024
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 2/25/2011
Evaluating safety culture and identifying perceived barriers to participation in voluntary reporting systems in radiation oncology.
Investigator: Jean Wright
Institutional Protocol #: 20110102
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Other
Phase: N/A
Enrolling Since: 2/21/2011
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen response in ER-Negative/Low Breast Cancer
Investigator: Judith Hurley
Institutional Protocol #: 20100252
National Clinical Trials Identifier: NCT01313039
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Pilot/Feasibility
Enrolling Since: 2/16/2011
AMC-075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20100787
National Clinical Trials Identifier: NCT01193842
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase I/II
Enrolling Since: 2/11/2011
AEWS1031 A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Investigator: Julio Barredo
Institutional Protocol #: 20110097
National Clinical Trials Identifier: NCT01231906
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 2/8/2011
ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.
Investigator: Julio Barredo
Institutional Protocol #: 20100658
National Clinical Trials Identifier: NCT01096368
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 2/8/2011
ARAR0332: Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy; A Groupwide Phase III Study
Investigator: Julio Barredo
Institutional Protocol #: 20070551
National Clinical Trials Identifier: NCT00304070
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 1/10/2011
A Phase I/II Trial of an-152 [Aezs-108] in Locally Advanced Unresectable or Metastatic Lhrh Positive Urothelial Carcinoma Patients who Failed Platinum Based Chemotherapy.
Investigator: Gustavo Fernandez
Institutional Protocol #: 20091095
National Clinical Trials Identifier: NCT01234519
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase I/II
Enrolling Since: 11/29/2010
Outcomes in Surgical Oncology: A Multi- Center Database
Investigator: Govindarajan Narayanan
Institutional Protocol #: 20100719
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Colorectal Cancer
Phase: N/A
Enrolling Since: 11/23/2010
ARAR0331, Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy
Investigator: Julio Barredo
Institutional Protocol #: 20080591
National Clinical Trials Identifier: NCT00274937
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 11/19/2010
AALL0631 A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL):Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)
Investigator: Julio Barredo
Institutional Protocol #: 20100028
National Clinical Trials Identifier: NCT00557193
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 11/5/2010
A Phase I Trial of MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer
Investigator: Alan Pollack
Institutional Protocol #: 20100389
National Clinical Trials Identifier: NCT01411319
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase I
Enrolling Since: 10/8/2010
TACL: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse):A joint study of TACL and POETIC
Investigator: John Goldberg
Institutional Protocol #: 20100137
National Clinical Trials Identifier: NCT00981799
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase I
Enrolling Since: 9/4/2010
GOG-0258 A Randomized Phase III Trial Of Cisplatin And Tumor Volume Directed Irradiation Followed By Carboplatin And Paclitaxel Vs. Carboplatin And Paclitaxel For Optimally Debulked, Advanced Endometrial Carcinoma
Investigator: Joseph Lucci
Institutional Protocol #: 20090859
National Clinical Trials Identifier: NCT00942357
Division: Cancer Center
Therapeutic Area: Gynecologic Cancer
Phase: Phase III
Enrolling Since: 8/6/2010
AHEP0731 Treatment of Children with All Stages of Hepatoblastoma
Investigator: Julio Barredo
Institutional Protocol #: 20100550
National Clinical Trials Identifier: NCT00980460
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 8/2/2010
AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Investigator: Julio Barredo
Institutional Protocol #: 20110038
National Clinical Trials Identifier: NCT01190930
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 7/27/2010
Pilot Study to Evaluate Myeloid Derived Suppressor Cells in Children with and without Cancer
Investigator: John Goldberg
Institutional Protocol #: 20100011
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Pilot/Feasibility
Enrolling Since: 7/19/2010
Translational Phase I Trial of Escalating Doses of 5-Chloro-2-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With External Beam Brain Radiation For Metastatic Carcinoma to the Brain - SCCC 2005097
Investigator: Brian Lally
Institutional Protocol #: 20057104
National Clinical Trials Identifier: NCT00521183
Division: Cancer Center
Therapeutic Area: Neurological Cancer
Phase: Phase I
Enrolling Since: 7/2/2010
AHOD0831 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma
Investigator: Julio Barredo
Institutional Protocol #: 20100481
National Clinical Trials Identifier: NCT01026220
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 6/22/2010
ECOG E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia. (SCCC 2009028)
Investigator: Deborah Glick
Institutional Protocol #: 20090473
National Clinical Trials Identifier: NCT00843882
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase III
Enrolling Since: 6/21/2010
A Novel Immunotherapy for Liver Transplant Patients with Hepatocellular Carcinoma: Anti-tumor Effect of IL2-activated Donor Liver Natural Killer Cell
Investigator: Seigo Nishida
Institutional Protocol #: 20100344
National Clinical Trials Identifier: NCT01147380
Division: Cancer Center
Therapeutic Area: Pancreatic, Liver, and Related Cancers
Phase: Phase I
Enrolling Since: 6/18/2010
Interrogation of Wnt, Notch and Hedgehog Activity in primary tumor samples
Investigator: Anthony Capobianco
Institutional Protocol #: 20100200
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Bone and Soft Tissue Cancers
Phase: N/A
Enrolling Since: 6/11/2010
AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443 ) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Investigator: Julio Barredo
Institutional Protocol #: 20100152
National Clinical Trials Identifier: NCT00873093
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase II
Enrolling Since: 6/10/2010
Primary cell culture generation from sarcoma patients tissues and biopsies.
Investigator: H. Thomas Temple
Institutional Protocol #: 20100167
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Bone and Soft Tissue Cancers
Phase: Pilot/Feasibility
Enrolling Since: 5/14/2010
Aptamer Based Strategy to Target CD44 Positive Head and Neck Squamous Cell Carcinoma Stem Cells (Project 2 Within the Bankhead-Coley Prespore Grant - PI Dr. W. J. Goodwin)
Investigator: Elizabeth Franzmann
Institutional Protocol #: 20090722
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: N/A
Enrolling Since: 5/14/2010
ARET0321: A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma
Investigator: Julio Barredo
Institutional Protocol #: 20090232
National Clinical Trials Identifier: NCT00554788
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 5/5/2010
AEWS07B1 A COG Study for Collecting and Banking Ewing Sarcoma Specimens
Investigator: Julio Barredo
Institutional Protocol #: 20100009
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 2/14/2010
Impact of Molecular Genetics on Disparities of Breast Cancer Risk and Prevention (Sccc 2009023)
Investigator: Jennifer Hu
Institutional Protocol #: 20090481
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: N/A
Enrolling Since: 11/16/2009
AEPI05N1 - Carcinogen Metabolism, DNA Repair, Parental Exposures, and Retinoblastoma
Investigator: Julio Barredo
Institutional Protocol #: 20090450
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 11/7/2009
SCCC 2009004: A phase I trial assessing the safety and feasibility of prophylactic nipple-areola complex (NAC) irradiation after nipple-sparing mastectomy and immediate reconstruction in patients with in-situ or invasive breast cancer
Investigator: Cristiane Takita
Institutional Protocol #: 20090299
National Clinical Trials Identifier: NCT01208974
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase I
Enrolling Since: 10/26/2009
SCCC2001028: Mechanisms and Control of Head and Neck
Investigator: Elizabeth Franzmann
Institutional Protocol #: 20010156
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: N/A
Enrolling Since: 8/5/2009
ANBL0531 Response- and Biology-Based Therapy for Intermediate-risk Neuroblastoma
Investigator: Julio Barredo
Institutional Protocol #: 20090566
National Clinical Trials Identifier: NCT00499616
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 6/25/2009
SCCC 2008133: Environmental Factors and Epigenetic Alterations in Head and Neck Cancer Disparities.
Investigator: W Jarrard Goodwin
Institutional Protocol #: 20081110
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: N/A
Enrolling Since: 6/3/2009
Ecog-1305:a Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer - 2008107
Investigator: Chukwuemeka Ikpeazu
Institutional Protocol #: 20081161
National Clinical Trials Identifier: NCT00588770
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: Phase III
Enrolling Since: 4/16/2009
SCCC 2008043: Phase II Study of Rituximab in Combination with Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and MESNA (R-MACLO/IVAM) in Patients with Previously Untreated Mantle Cell Lymphoma
Investigator: Izidore Lossos
Institutional Protocol #: 20080803
National Clinical Trials Identifier: NCT00878254
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase II
Enrolling Since: 3/12/2009
ARST0531 - Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
Investigator: Julio Barredo
Institutional Protocol #: 20080572
National Clinical Trials Identifier: NCT00354835
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 3/3/2009
AALL0433 Intensive Treatment for Intermediate-Risk Relapse of Childhood b-Precursor Acute Lymphoblastic Leukemia (all): a Randomized Trial of Vincristine Strategies
Investigator: Julio Barredo
Institutional Protocol #: 20090068
National Clinical Trials Identifier: NCT00381680
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 2/26/2009
Facilitating adjustment in low-income black women with breast cancer
Investigator: Suzanne Lechner
Institutional Protocol #: 20081005
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: N/A
Enrolling Since: 12/11/2008
Risk Factor Analysis of Hereditary Breast and Ovarian Cancer (SCCC 2007109)
Investigator: Joseph Lucci
Institutional Protocol #: 20080250
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Gynecologic Cancer
Phase: N/A
Enrolling Since: 12/2/2008
Sccc 2008001: a Phase I Trial of Weekly and Every Three Weeks Ixabepilone and Sunitinib in Solid Tumor Patients
Investigator: Jaime Merchan
Institutional Protocol #: 20080376
National Clinical Trials Identifier: NCT00884676
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase I
Enrolling Since: 11/14/2008
Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity (SCCC 2008035)
Investigator: Jennifer Hu
Institutional Protocol #: 20070906
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: N/A
Enrolling Since: 11/11/2008
Sccc# 2008082 Rtog: 0534 a Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate bed Only Radiotherapy (Spport) in Prostate Cancer Patients With a Rising psa After Radical Prostatectomy
Investigator: Alan Pollack
Institutional Protocol #: 20080762
National Clinical Trials Identifier: NCT00567580
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: Phase III
Enrolling Since: 11/11/2008
A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer - Sccc 2008002
Investigator: Joyce Slingerland
Institutional Protocol #: 20080325
National Clinical Trials Identifier: NCT01216176
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: Phase I/II
Enrolling Since: 10/21/2008
ANBL0532: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma.
Investigator: Julio Barredo
Institutional Protocol #: 20081137
National Clinical Trials Identifier: NCT00567567
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 10/17/2008
SCCC 2008006: Pilot study of Phosphodioesterase-5 inhibitor Tadalafil(Cialis) as an immunomodulator in patients with oral cavity and oropharyngeal squamous cell carcinoma.
Investigator: Donald Weed
Institutional Protocol #: 20070918
National Clinical Trials Identifier: NCT00843635
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: Pilot/Feasibility
Enrolling Since: 9/24/2008
Treatment Plan: Umbilical Cord Blood (ucb) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Using Conditioning Regimen Without Radiation
Investigator: Martin Andreansky
Institutional Protocol #: 20080774
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 8/25/2008
Use of Non-Invasive Computerized Tomographic Software data to determine Treatment endpoints during CT guided Radiofrquency Ablation of Renal Masses
Investigator: Raymond Leveillee
Institutional Protocol #: 20080395
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: N/A
Enrolling Since: 7/30/2008
Analysis of Thyroid Function in Patients with Colorectal Cancer
Investigator: Caio Max Rocha Lima
Institutional Protocol #: 20071032
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Colorectal Cancer
Phase: N/A
Enrolling Since: 7/21/2008
AREN0321: Treatment of High Risk Renal Tumors: A Groupwide Phase II Study
Investigator: Julio Barredo
Institutional Protocol #: 20070555
National Clinical Trials Identifier: NCT00335556
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase II
Enrolling Since: 6/3/2008
AREN0532: Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor
Investigator: Julio Barredo
Institutional Protocol #: 20070546
National Clinical Trials Identifier: NCT00352534
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 5/15/2008
AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor
Investigator: Julio Barredo
Institutional Protocol #: 20070543
National Clinical Trials Identifier: NCT00379340
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 5/15/2008
Identification and therapeutic targeting of molecular pathways associated with brain metastasis of primary melanoma
Investigator: Ronald Benveniste
Institutional Protocol #: 20071046
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Melanoma and Related Skin Cancers
Phase: N/A
Enrolling Since: 4/14/2008
AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
Investigator: Julio Barredo
Institutional Protocol #: 20070540
National Clinical Trials Identifier: NCT00408005
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 1/15/2008
AALL06N1: A Study of Neurocognitive Function in Children Treated for ALL
Investigator: Julio Barredo
Institutional Protocol #: 20070556
National Clinical Trials Identifier: NCT00437060
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 11/27/2007
Detection of melanoma by canine olfactory receptors
Investigator: Tatjana Abaffy
Institutional Protocol #: 20061117
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Melanoma and Related Skin Cancers
Phase: N/A
Enrolling Since: 7/23/2007
AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.
Investigator: Julio Barredo
Institutional Protocol #: 20070561
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 7/17/2007
AHOD04B1: Hodgkin Disease (HD) Banking Study
Investigator: Julio Barredo
Institutional Protocol #: 20070559
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 5/10/2007
SCCC 2006117: Salivary Soluble Markers in Head and Neck Cancer
Investigator: Elizabeth Franzmann
Institutional Protocol #: 20061017
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: N/A
Enrolling Since: 4/5/2007
ACNS0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients.
Investigator: Julio Barredo
Institutional Protocol #: 20070437
National Clinical Trials Identifier: NCT00392327
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 3/28/2007
Sccc 2006069: Multicenter Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large b-Cell Lymphoma Patients Treated With r-Chop
Investigator: Izidore Lossos
Institutional Protocol #: 20061138
National Clinical Trials Identifier: NCT00450385
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase II
Enrolling Since: 2/7/2007
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer - SCCC 2006065
Investigator: Michael Antoni
Institutional Protocol #: 20060496
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Breast Cancer
Phase: N/A
Enrolling Since: 10/12/2006
Estrogen/ Estrogen Receptor-mediated lung diseases.
Investigator: Marilyn Glassberg Csete
Institutional Protocol #: 20060249
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Thoracic Oncology
Phase: N/A
Enrolling Since: 8/16/2006
AREN03B2: Renal Tumors Classification, Biology and Banking Study.
Investigator: Julio Barredo
Institutional Protocol #: 20060374
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 5/22/2006
A Prospective Observational Trial Of Serial CT Based Imaging For The Detection Of Dosimetric Changes During Intensity Modulated Radiation Therapy (IMRT) For Advanced Cancers Of The Head And Neck (SCCC #2005112)
Investigator: Cristiane Takita
Institutional Protocol #: 20060212
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: N/A
Enrolling Since: 3/30/2006
AOST0331 A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy.
Investigator: Julio Barredo
Institutional Protocol #: 20057605
National Clinical Trials Identifier: NCT00134030
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 3/7/2006
Phase II Study of Ibritumomab Tiuxetan (Zevalin) in Patients With Previously Untreated Marginal Zone Lymphoma (Sccc 2005133)
Investigator: Izidore Lossos
Institutional Protocol #: 20060078
National Clinical Trials Identifier: NCT00453102
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: Phase II
Enrolling Since: 2/27/2006
ANBL00P3: A phase III randomized trial of intravenous gammaglobulin therapy for patients with neuroblastoma associated opsoclonus-myoclonusataxia syndrome treated with chemotherapy and prednisone.
Investigator: Julio Barredo
Institutional Protocol #: 20057575
National Clinical Trials Identifier: NCT00033293
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 1/5/2006
"COG LTF: A Groupwide Process For Collecting Long Term Follow Up Data"
Investigator: Julio Barredo
Institutional Protocol #: 20043114
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 9/1/2005
AALL0232: High Risk B-precursor Acute Lymphoblastic Leukemia
Investigator: Julio Barredo
Institutional Protocol #: 20057087
National Clinical Trials Identifier: NCT00075725
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 8/18/2005
ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal, Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk, Medulloblastoma: A Phase III Double Randomized Trial
Investigator: Julio Barredo
Institutional Protocol #: 20043354
National Clinical Trials Identifier: NCT00085735
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: Phase III
Enrolling Since: 8/16/2005
Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Ecog Treatment Trials for Leukemia or Related Hematologic Disorders
Investigator: Mark Goodman
Institutional Protocol #: 20043176
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: N/A
Enrolling Since: 8/12/2005
AEWS0331: European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E.W.I.N.G. 99)
Investigator: Julio Barredo
Institutional Protocol #: 20030768
National Clinical Trials Identifier: NCT00020566
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 8/2/2005
Neuroblastoma Biology Studies, COG #ANBL00B1/SCCC 2001002
Investigator: Julio Barredo
Institutional Protocol #: 20010127
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 6/16/2005
ABTR01B1: a Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Investigator: Julio Barredo
Institutional Protocol #: 20040264
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 7/22/2004
Molecular Markers in the Blood and Tissues of Prostate Cancer Patients (Sccc 2003147)
Investigator: Rakesh Singal
Institutional Protocol #: 20030779
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Prostate, Bladder, and Kidney Cancers
Phase: N/A
Enrolling Since: 1/14/2004
D9902: a cog Soft Tissue Sarcoma Biology and Banking Protocol
Investigator: Julio Barredo
Institutional Protocol #: 20000366
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Pediatric Cancer
Phase: N/A
Enrolling Since: 12/29/2003
"Study of Blood, Tissue and Body Fluids of Viral Associated Malignancies"
Investigator: Juan Carlos Ramos
Institutional Protocol #: 20030608
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: N/A
Enrolling Since: 9/16/2003
Clinical and Pathologic Studies in non-Hodgkin's Lymphoma and Hodgkin's Disease (Sccc 2003043)
Investigator: Izidore Lossos
Institutional Protocol #: 20030255
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Leukemia, Lymphoma, and Myeloma
Phase: N/A
Enrolling Since: 6/11/2003
Molecular Mechanism of Drug Resistance/Sensitivity; Sccc 1999078
Investigator: Lynn Feun
Institutional Protocol #: 19990582
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Melanoma and Related Skin Cancers
Phase: N/A
Enrolling Since: 2/25/2000
SCCC 2001067: Tumor Radiosensitization With 5-Cl deoxycytidine and Biomodulators of its Metabolism.
Investigator: Sheldon Greer
Institutional Protocol #: 19980114
National Clinical Trials Identifier: N/A
Division: Cancer Center
Therapeutic Area: Head and Neck Cancer
Phase: N/A
Enrolling Since: 7/10/1998